The CDH12 antibody targets cadherin-12 (CDH12), a calcium-dependent cell adhesion molecule belonging to the type-II classical cadherin family. Cadherins play critical roles in tissue morphogenesis, cell-cell adhesion, and signaling. CDH12 is primarily expressed in the nervous system, where it contributes to neural circuit formation, synaptic plasticity, and neuronal migration during development. It is also implicated in cancer progression, particularly in malignancies like glioblastoma and breast cancer, where aberrant CDH12 expression correlates with tumor invasiveness and metastasis.
CDH12 antibodies are essential tools for studying its localization, expression levels, and functional interactions in both physiological and pathological contexts. They are widely used in techniques such as immunohistochemistry (IHC), Western blotting (WB), and immunofluorescence (IF) to investigate CDH12's role in neural development, cancer biology, and neurodegenerative disorders. Recent research explores CDH12's potential as a biomarker or therapeutic target, given its involvement in cell adhesion pathways and epithelial-mesenchymal transition (EMT). However, its precise mechanisms remain under investigation, necessitating high-specificity antibodies to minimize cross-reactivity with other cadherins. Commercial CDH12 antibodies are typically validated for human, mouse, and rat samples, supporting translational research across model systems.